Xellia Pharmaceuticals ApS
About Xellia Pharmaceuticals ApS
Xellia Pharmaceuticals ApS Industry Content
Certifications
-
CE -
FDA -
GMP -
ISO
Categories
-
DK -
2015On CPHI since
-
4Certificates
-
1000 - 4999Employees
Company types
Primary activities
Contact info
-
-
-
Dalslandsgade 11, 2300, Copenhagen, Denmark
.jpg)
.jpg)
.jpg)
Meet us at
CPHI Barcelona 2023
Fira Barcelona Gran Via, Spain
24-26 October 2023
Products from Xellia Pharmaceuticals ApS (22)
-
Product Amphotericin B
Amphotericin B is a mixture of polyenes active against a wide variety of fungi e.g. Aspergillus, Candida and Cryptococcus species.
Indication: Used in the treatment of severe, invasive, potentially life-threatening fungal infections (mycosis) typically in immunocompromised patients. q... -
Product Bacitracin
Bacitracin is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci.
Indication: Used locally for the treatment of infections of the skin, ear and eye or for intramuscular use in infants for the... -
Product Bacitracin zinc
Bacitracin zinc is composed of a group of polypeptides with antibiotic activity against a variety of Gram-positive bacteria including staphylococci. The zinc complex adds stability to the component, making bacitracin zinc more stable compared to bacitracin.
Indication: Used in the treatm... -
Product Colistimethate sodium (CMS)
Colistimethate sodium is a prodrug of colistin (polymyxin E) which is a mixture of polypeptide antibiotics active against Gram-negative bacteria, including Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa.
I... -
Product Daptomycin
Daptomycin is a lipopeptide antibiotic active against Gram-positive bacteria such as Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp. equisimilis, and Enterococcus faecalis (vancomycin-susceptible isol... -
Product Gramicidin
Gramicidin is a mixture of linear polypeptides active against a variety of Gram-positive bacteria.
Indication: Ophthalmic solution is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria, such... -
Product Polymyxin B sulfate
Polymyxin B sulfate is a mixture of sulfates of polypeptide antibiotics active against Pseudomonas aeruginosa and other Gram-negative bacteria.
Indication: Used in the treatment of acute urinary, meningeal or blood stream infections due to Pseudomonas aeruginosa and other ... -
Product Tobramycin sulfate
Tobramycin sulfate is the sulfate salt of tobramycin, an aminoglycoside antibiotic active against Gram-negative bacteria including most Enterobacteriaceae, Pseudomonas aeruginosa and a few Gram-positive bacteria such as Staphylococcus aureus.
Indication: Use... -
Product Tyrothricin
Tyrothricin contains about 20% gramicidin and 80% tyrocidine and belongs to the family of polypeptide antibiotics. It is active against a variety of Gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus and bacteria causing diphtheria.
... -
Product Vancomycin hydrochloride (manufactured in Budapest, Hungary)
Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroids, en... -
Product Vancomycin hydrochloride (manufactured in Copenhagen, Denmark)
Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid... -
Product Vancomycin hydrochloride (manufactured in Taizhou, China)
Vancomycin hydrochloride is a glycopeptide antibiotic active against a wide variety of Gram-positive bacteria, most important being staphylococci, including Staphylococcus aureus and Staphylococcus epidermidis (including heterogeneous methicillin-resistant strains), but also active against diphtheroid...
Xellia Pharmaceuticals ApS Resources (11)
-
News Xellia Pharmaceuticals Cleveland, Ohio manufacturing facility commercially operational for production of key anti-infective drug products for US hospitals and patients
Copenhagen, Denmark, and Buffalo Grove, Illinois, US, 17 August 2021 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, announces that its manufacturing site in Cleveland, Ohio is now commercially operational and has released the first anti-infectives manufactured at the site, to be distributed for use by US hospitals. -
Brochure Xellia Pharmaceuticals Corporate Report 2022
Committed to patients in a year impacted by COVID-19During 2020, our main focus was on maintaining full production and reliable supply of Xellia’s critical care products, while also ensuring the safety of our employees.
Read more in Xellia's Corporate Report 2020 -
News Xellia has signed the UN Women’s Empowerment Principles
Xellia Pharmaceuticals has adopted the United Nations Women’s Empowerment Principles (WEPs) as part of its commitment to promoting gender equality and women’s empowerment in the workplace, marketplace and community
Copenhagen, Denmark, 15 April 2021 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments, is pleased to announce the signing of the UN Women’s Empowerment Principles by Xellia’s President and CEO, Carl-Åke Carlsson. On March 31, 2021 Xellia became an official signatory, making Xellia one of the 16 companies enlisted in Denmark to date. -
Technical Data Xellia Corporate Introduction
Xellia Pharmaceuticals is a specialty pharmaceutical company developing,manufacturing and commercializing anti-infective treatments againstserious and often life-threatening bacterial and fungal infections. Xellia isa world-leading trusted supplier of several important established antiinfectivedrugs, comprising active pharmaceutical ingredients as well asfinished dosage forms, where the majority are injectable drug products.Headquartered in Copenhagen, Denmark and owned by Novo HoldingsA/S, Xellia Pharmaceuticals has more than 1800 employees globally.From state-of-the-art manufacturing sites in the U.S., China, Denmarkand Hungary to R&D sites in Norway and Croatia; Xellia Pharmaceuticalsexcels within innovative product development to deliver high qualityproducts to its customers. -
News Cleveland, Ohio, passes FDA inspection of Injectable Drug Manufacturing Methods, Facilities, Processes & Controls
Cleveland site to manufacture Xellia's aseptic injectables for the US market
Copenhagen, Denmark, 26 March 2020 - Xellia Pharmaceuticals (‘Xellia’), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has received inspection sign-off from the US Food and Drug Administration (FDA) enabling the Company to commence manufacturing of drug products at its Cleveland, Ohio site. -
-file109395.jpg)
Video Corporate film
Xellia Pharmaceuticals operates internationally, with sales offices and production sites found across the globe. Xellia Pharmaceuticals is the leading supplier of important anti-infectives vancomycin, colistimethate sodium and daptomycin. We are vertically integrated from Active Pharmaceutical Ingredients (APIs) to Finished Dosage Forms (FDFs), with 150+ research and development scientists, and robust production sites. -
News Xellia Pharmaceuticals Opens New Commercial Office in Dubai
Xellia Pharmaceuticals Opens New Commercial Office in Dubai -
-file109210.jpg)
Video Molecule to Market: Podcast with Carl-Åke Carlsen, CEO & President, Xellia Pharmaceuticals
We are pleased to share the podcast: Molecule to Market – featuring our CEO, Carl-Åke Carlsson. The host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Carl-Åke, covering Xellia’s journey from an API supplier to a global specialty pharmaceutical company; producing anti-infective treatments. Carl‑Åke speaks about his journey from his position in finance to CEO and the transformation of Xellia as a company over the years; offering advice and insight from his experiences. Molecule to Market is sponsored and funded by Ramarketing, an international content, design and digital agency. Click the link here to access the podcast: https://apple.co/32a0RW0 or at https://spoti.fi/3jXjgLS -
Video Xellia Manufacturing Collage 2023
Xellia Manufacturing Collage 2023 -
Video Sustainability and AMR advocacy
Sustainability and AMR advocacy -
Video Xellia and SOS Children’s Villages partnership
Xellia and SOS Children’s Villages partnership
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance